December 2008 Volume 22 Number 12, pp 2137 - 2294
-----------------------------------------------------------------------------
A supplement on Myeloproliferative Disease accompanies the December issue of
Leukemia and is sponsored by Merck, TargeGen and Celgene.
To view this collection of Spotlight Reviews FREE online go to
http://links.ealert.nature.com/ctt?kn=57&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0.
------------------------------------------------------------------------------
Why Publish in Leukemia?
Efficient peer-review, hassle-free submission, recognition...
Papers benefit from wide readership through hosting on nature.com and inclusion
in the leading abstracting and indexing services.
Rapid publication is also assured through Advance Online Publication.
To read the full Guide to Authors for Leukemia, visit
http://links.ealert.nature.com/ctt?kn=101&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
-------------------------------------------------------------------------------
----------------------
REVIEW
----------------------
Etiology of common childhood acute lymphoblastic leukemia: the adrenal
hypothesis
K Schmiegelow, T Vestergaard, S M Nielsen and H Hjalgrim
Abstract: http://links.ealert.nature.com/ctt?kn=74&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=98&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
----------------------
ORIGINAL ARTICLES
----------------------
Factors influencing survival after relapse from acute lymphoblastic leukemia: a
Children's Oncology Group study
K Nguyen, M Devidas, S-C Cheng, M La, E A Raetz, W L Carroll, N J Winick,
S P Hunger, P S Gaynon and M L Loh
Abstract: http://links.ealert.nature.com/ctt?kn=17&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=53&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their
differentiation
S Tavor, M Eisenbach, J Jacob-Hirsch, T Golan, I Petit, K BenZion, S Kay, S Baron,
N Amariglio, V Deutsch, E Naparstek and G Rechavi
Abstract: http://links.ealert.nature.com/ctt?kn=5&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=60&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor
to induce growth arrest and differentiation of acute myelogenous leukemia cells
C Nishioka, T Ikezoe, J Yang, H P Koeffler and A Yokoyama
Abstract: http://links.ealert.nature.com/ctt?kn=39&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=6&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
SOCS2: inhibitor of JAK2V617F-mediated signal transduction
H Quentmeier, R Geffers, E Jost, R A F MacLeod, S Nagel, S Rohrs, J Romani, M Scherr,
M Zaborski and H G Drexler
Abstract: http://links.ealert.nature.com/ctt?kn=4&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=13&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with
chronic myeloid leukemia in blast phase
J Cortes, D-W Kim, E Raffoux, G Martinelli, E Ritchie, L Roy, S Coutre, S Corm,
N Hamerschlak, J-L Tang, A Hochhaus, H J Khoury, T H Brummendorf, M Michallet,
G Rege-Cambrin, C Gambacorti-Passerini, J P Radich, T Ernst, C Zhu, J M A Van Tornout
and M Talpaz
Abstract: http://links.ealert.nature.com/ctt?kn=124&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=38&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia
J B Weinberg, A D Volkheimer, M Mihovilovic, N Jiang, Y Chen, K Bond, J O Moore,
J P Gockerman, L F Diehl, C M de Castro, D A Rizzieri, M C Levesque, R DeKroon and
W J Strittmatter
Abstract: http://links.ealert.nature.com/ctt?kn=104&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=36&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Minimal residual disease is an important predictive factor of outcome in children
with relapsed /'high-risk/' acute lymphoblastic leukemia
M Paganin, M Zecca, G Fabbri, K Polato, A Biondi, C Rizzari, F Locatelli and G Basso
Abstract: http://links.ealert.nature.com/ctt?kn=111&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=22&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Regulation of IL-2 expression by transcription factor BACH2 in umbilical cord blood
CD4+ T cells
M L Lesniewski, P Haviernik, R P Weitzel, S Kadereit, M M Kozik, L R Fanning, Y C Yang,
Y Hegerfeldt, M R Finney, M Z Ratajczak, N Greco, P Paul, J Maciejewski and M J Laughlin
Abstract: http://links.ealert.nature.com/ctt?kn=87&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=82&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1
and BCR-ABL1 fusion protein kinases
K De Keersmaecker, M Versele, J Cools, G Superti-Furga and O Hantschel
Abstract: http://links.ealert.nature.com/ctt?kn=30&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=10&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
ICER expression inhibits leukemia phenotype and controls tumor progression
M Pigazzi, E Manara, E Baron and G Basso
Abstract: http://links.ealert.nature.com/ctt?kn=25&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=125&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Structural aberrations affecting the MYC locus indicate a poor prognosis independent
of clinical risk factors in diffuse large B-cell lymphomas treated within randomized
trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
W Klapper, H Stoecklein, S Zeynalova, G Ott, F Kosari, A Rosenwald, M Loeffler, L Trumper,
M Pfreundschuh and Reiner Siebert
Abstract: http://links.ealert.nature.com/ctt?kn=85&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=91&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Malignant Tregs express low molecular splice forms of FOXP3 in Sezary syndrome
T Krejsgaard, L M Gjerdrum, E Ralfkiaer, B Lauenborg, K W Eriksen, A-M Mathiesen,
L F Bovin, R Gniadecki, C Geisler, L P Ryder, Q Zhang, M A Wasik, N Odum and A Woetmann
Abstract: http://links.ealert.nature.com/ctt?kn=62&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=37&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
A role for IFN-[lambda]1 in multiple myeloma B cell growth
A J Novak, D M Grote, S C Ziesmer, V Rajkumar, S E Doyle and S M Ansell
Abstract: http://links.ealert.nature.com/ctt?kn=66&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=115&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an
effective regimen for relapsed//refractory myeloma and is associated with improvement of
abnormal bone metabolism and angiogenesis
E Terpos, E Kastritis, M Roussou, D Heath, D Christoulas, N Anagnostopoulos,
E Eleftherakis-Papaiakovou, K Tsionos, P Croucher and M A Dimopoulos
Abstract: http://links.ealert.nature.com/ctt?kn=108&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=123&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
----------------------
LETTERS TO THE EDITOR
----------------------
How little is too much? p53 inactivation: from laboratory cutoff to biological basis
of chemotherapy resistance
T Zenz, S Habe, T Denzel, D Winkler, H Dohner and S Stilgenbauer
http://links.ealert.nature.com/ctt?kn=93&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Claimed association of absolute lymphocyte count with therapeutic efficacy of radio-immunotherapy
in patients with indolent lymphoma cannot be verified in an independent data set
M J Bishton, R J Hicks, H M Prince, D S Ritchie, M Wolf and J F Seymour
http://links.ealert.nature.com/ctt?kn=94&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Reply to /'Claimed association of absolute lymphocyte count with therapeutic efficacy of
radio-immunotherapy in patients with indolent lymphoma cannot be verified in an independence
data set/' by Mark J Bishton et al
L F Porrata, K Ristow, T E Witzig, N Tuinistra, T M Habermann, D J Inwards, S M Ansell,
I N Micallef, P B Johnston and S N Markovic
http://links.ealert.nature.com/ctt?kn=49&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus
H Deng, N Tang, A E Stief, N Mehta, E Baig, R Head, G Sleep, X-Z Yang, C McKerlie, S Trudel,
A K Stewart and J A McCart
http://links.ealert.nature.com/ctt?kn=109&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Improving minimal residual disease detection in precursor B-ALL based on immunoglobulin-[kappa]
and heavy-chain gene rearrangements
R Sutton, A Y Bahar, E Kwan, J E Giles, N C Venn, S Tran, N Hackenberg, L Dalla Pozza, G M Marshall,
M Haber, V H J van der Velden and M D Norris
http://links.ealert.nature.com/ctt?kn=24&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
PKR is activated in MDS patients and its subcellular localization depends on disease severity
M Y Follo, C Finelli, S Mongiorgi, C Clissa, C Bosi, G Martinelli, W L Blalock, L Cocco and
A M Martelli
http://links.ealert.nature.com/ctt?kn=45&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia
A Agarwal, C A Eide, A Harlow, A S Corbin, M J Mauro, B J Druker, C L Corless, M C Heinrich and
M W Deininger
http://links.ealert.nature.com/ctt?kn=43&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Cotransplantation of mesenchymal cells and a higher relapse rate: a role for HLA-G molecules?
R Rizzo, D Campioni, F Lanza and O R Baricordi
http://links.ealert.nature.com/ctt?kn=41&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Notch inhibition blocks multiple myeloma cell-induced osteoclast activation
R Schwarzer, M Kaiser, O Acikgoez, U Heider, S Mathas, R Preissner, O Sezer, B Doerken and F Jundt
http://links.ealert.nature.com/ctt?kn=107&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Spurious elevation of the cerebrospinous fluid white cell counts in three patients receiving
liposomal cytarabine as part of post-remission therapy
R Swords, C O'Rafferty, F Giles and P Browne
http://links.ealert.nature.com/ctt?kn=1&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Novel gain-of-function mutation in the extracellular domain of the PDGFRA gene in infant acute
lymphoblastic leukemia with t(4;11)(q21;q23)
M Hiwatari, R Ono, T Taki, A Hishiya, E Ishii, T Kitamura, Y Hayashi and T Nosaka
http://links.ealert.nature.com/ctt?kn=80&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Clinical and biological significance of RAS mutations in multiple myeloma
W J Chng, N Gonzalez-Paz, T Price-Troska, S Jacobus, S V Rajkumar, M M Oken, R A Kyle,
K J Henderson, S Van Wier, P Greipp, B Van Ness and R Fonseca
http://links.ealert.nature.com/ctt?kn=71&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Large interindividual differences in cellular sensitivity to calicheamicin may influence
gemtuzumab ozogamicin response in acute myeloid leukemia
B F Goemans, C M Zwaan, S J H Vijverberg, A H Loonen, U Creutzig, K Hahlen, D Reinhardt,
B E S Gibson, J Cloos and G J L Kaspers
http://links.ealert.nature.com/ctt?kn=110&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid
leukaemia
M P Martelli, N Manes, A Liso, V Pettirossi, B Verducci Galletti, B Bigerna, A Pucciarini,
M F De Marco, M T Pallotta, N Bolli, M Sborgia, F di Raimondo, F Fabbiano, G Meloni, G Specchia,
M F Martelli and B Falini
http://links.ealert.nature.com/ctt?kn=113&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR
O Pelz-Ackermann, M Cross, H Pfeifer, M Deininger, S-Y Wang, H K Al-Ali, D Niederwieser and T Lange
http://links.ealert.nature.com/ctt?kn=2&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
----------------------
CORRIGENDA
----------------------
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective
regimen for relapsed//refractory myeloma and is associated with improvement of abnormal bone metabolism
and angiogenesis
E Terpos, E Kastritis, M Roussou, D Heath, D Christoulas, N Anagnostopoulos, E Eleftherakis-Papaiakovou,
K Tsionos, P Croucher and M A Dimopoulos
http://links.ealert.nature.com/ctt?kn=7&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
Regulation of IL-2 expression by transcription factor BACH2 in umbilical cord blood CD4+T cells
M L Lesniewski, P Haviernik, R P Weitzel, S Kadereit, M M Kozik, L R Fanning, Y C Yang, Y Hegerfeldt,
M R Finney, M Z Ratajczak, N Greco, P Paul, J Maciejewski and M J Laughlin
http://links.ealert.nature.com/ctt?kn=96&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
-------------------------------------------------------------------------------------------------------------
Are you looking to reach a highly-skilled market for your recruitment
or classified ads?
Nature Publishing Group can offer you a portfolio of prestigious journals that
are targeted down to a specific sub-specialization. With over 40 specialist
titles to choose from, you can attract a highly-skilled targeted audience within
a number of scientific disciplines. Both print and online options are available.
Contact your Naturejobs regional representative today:
W: www.naturejobs.com/advertisers/contact.html
E: naturejobs@nature.com
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to receive it.
You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=18&m=30728708&r=MTQ1ODkyNDU5MgS2&b=2&j=NDQwOTQ5NTMS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne - San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
© Copyright 2008 Nature Publishing Group
=====================================================================
